Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Assets Average (2016 - 2025)

Historic Assets Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $579.7 million.

  • Viridian Therapeutics, Inc.\DE's Assets Average fell 1459.24% to $579.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579.7 million, marking a year-over-year decrease of 1459.24%. This contributed to the annual value of $616.4 million for FY2024, which is 3320.44% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Assets Average is $579.7 million, which was down 1459.24% from $621.7 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Assets Average ranged from a high of $757.2 million in Q4 2024 and a low of $120.5 million during Q2 2021
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Assets Average value was $409.6 million (recorded in 2023), while the average stood at $409.5 million.
  • Its Assets Average has fluctuated over the past 5 years, first skyrocketed by 41178.71% in 2021, then plummeted by 1459.24% in 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Assets Average (Quarter) stood at $212.5 million in 2021, then soared by 106.08% to $437.8 million in 2022, then decreased by 6.45% to $409.6 million in 2023, then soared by 84.86% to $757.2 million in 2024, then fell by 23.43% to $579.7 million in 2025.
  • Its Assets Average stands at $579.7 million for Q3 2025, versus $621.7 million for Q2 2025 and $701.7 million for Q1 2025.